

ERNIE FLETCHER
GOVERNOR

CABINET FOR HEALTH AND FAMILY SERVICES

DEPARTMENT FOR MEDICAID SERVICES
COMMISSIONER'S OFFICE
275 EAST MAIN STREET, 6W-A
FRANKFORT, KENTUCKY 40621-0001
(502) 564-4321 (502) 564-0509 FAX
WWW.KENTUCKY.GOV

JAMES W. HOLSINGER, JR., M.D. SECRETARY

December 16, 2004

Dear Provider:

This letter provides important information about changes to the Medicaid Pharmacy Program, including modification of drug prior authorization (PA) requirements. Changes are based on recommendations from the Kentucky Department for Medicaid Services. First Health Services, the Pharmacy Benefit Administrator for the Kentucky Medicaid Pharmacy Program, will initiate Prior Authorization requirements on atypical, second-generation antipsychotics, effective January 16, 2005.

Please fax requests for Prior Authorization to First Health at FAX # 800-365-8835.

Atypical Antipsychotics: The following changes are effective January 16, 2005.

• The following atypical antipsychotics will be placed on the preferred drug list for all recipients, including long term care, but excluding pediatric patients (dosage, duplicate therapy, and ICD-9 requirements will apply):

Risperdal (oral)

Risperdal-M (oral)

Seroquel (oral)

Geodon (oral)

Clozaril (oral)

• Prior Authorization will be required for the following non-preferred drugs (dosage, duplicate therapy, and ICD-9 requirements will apply):

Zyprexa (oral)

Zyprexa Zydis (oral)

Abilify (oral)

Symbyax (oral)

- There will be no preferred atypical antipsychotics for a recipient less than 18 years of age (dosage limit, duplicate therapy, and ICD-9 requirements apply).
- Patients currently on a non-preferred atypical (Zyprexa, Zyprexa Zydis, Abilify, Symbyax) and active in the Medicaid system will be permitted to continue with their current medication <u>only if</u> <u>dosage, and ICD-9 requirements are met.</u> New patients to the Medicaid program will not be grandfathered.
- All prescriptions, pediatric and adult, for atypical antipsychotics will only be filled for appropriate diagnoses (see attached). The prescriber must write either the appropriate ICD-9 code

or the diagnosis on the prescription. If the prescriber chooses not to do so, a prior authorization form must be completed with the ICD-9 code and diagnosis written on the PA form. The pharmacy provider will be required to submit an ICD-9 code when submitting a claim to Medicaid. The ICD-9 code will be submitted in Field 424-DO.

Acceptable ICD-9 Codes Adults:

```
290 & subsets SENILE/PRESENILE PSYCHOS (Dementia related Psychoses)
```

293 & subsets DELIRIUM

294 & subsets OTHER ORGANIC PSYCH COND 295 & subsets SCHIZOPHRENIC DISORDERS

296 & subsets AFFECTIVE PSYCHOSES (bipolar disorders)

298 & subsets Psychoses

300.14 MULTIPLE PERSONALITY
 301.20 Schizoid personality disorders
 301.21 Schizoid personality disorders
 301.22 Schizoid personality disorders

Acceptable ICD-9 Codes Pediatrics (under 18 years) :

294 & subsets OTHER ORGANIC PSYCH COND 295 & subsets SCHIZOPHRENIC DISORDERS

296 & subsets AFFECTIVE PSYCHOSES (bipolar disorders)

298 & subsets Psychoses

299 & subsets Psychoses - pediatric

300.14 MULTIPLE PERSONALITY
301.20, 301.21, 301.22 Schizoid personality disorders
315 & subsets Pervasive Developmental Disorders
307.20, 307.21, 307.22, 307.23 Tourette's Disorder, Including Tics
309 & subsets Reactive Adjustment Disorders
299 & subsets Autism Spectrum Disorders
313.81 Opposition Defiance Disorder

- Duplicate Therapy Criteria:
 - Patients who are on two agents will be grandfathered (allowed to continue).
 - Patients who are on three agents will require PA.
 - Addition of a second agent to existing monotherapy will require PA.
- Doses above the maximum FDA-approved daily dose will require PA.

Abilify 30mg per day Zvprexa 20mg per day Zyprexa Zydis 20mg per day 18mg/75mg per day Symbyax Geodon 160mg per day Risperdal 16mg per day 16mg per day Risperdal-M Seroquel 800mg per day Clozaril 900mg per day

 Quantity limits, as previously recommended, will be evaluated via Retrospective Drug Utilization Review. Analysis of the profile reviews will determine possible future implementation of quantity limits.

Internet Web Site:

Medicaid's web site at **http://chfs.ky.gov/dms/** provides information about the Medicaid Pharmacy Program and related topics such as pharmacy provider letters, Pharmacy and Therapeutics Advisory Committee meetings and recommendations.

Contact Information:

For Questions About	Contact	<u>Phone</u>
Previously sent drug PA requests	Prior Authorization Help Desk	800-477-3071 (NEW)
Billing of pharmacy claims	Provider Help Desk	800-432-7005 (NEW)
This letter or Medicaid policies	Pharmacy Department	502-564-7940

Sincerely, Hannon Turner

Shannon Turner Commissioner